Drugs / Conditioning chemotherapy
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02356159 Background | Sep 2015 → Dec 2024 | Hodgkins lymphoma, acute leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma +1 | National Cancer Institute (NCI) | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conditioning chemotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02356159 ↗ |
| Route | Intravenous | “1200 mg/m\^2 per day IV infusion” NCT02356159 ↗ |